140 related articles for article (PubMed ID: 36282771)
1. 26-Week Open-Label Extension Study Evaluating the Safety and Tolerability of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar I Disorder (Most Recent Episode Manic).
Atkinson S; Bachinsky M; Raiter Y; Abreu P; Ianos C; Chappell P; Findling RL
J Child Adolesc Psychopharmacol; 2022 Oct; 32(8):453-458. PubMed ID: 36282771
[No Abstract] [Full Text] [Related]
2. Efficacy, Safety, and Tolerability of Flexibly Dosed Ziprasidone in Children and Adolescents with Mania in Bipolar I Disorder: A Randomized Placebo-Controlled Replication Study.
Findling RL; Atkinson S; Bachinsky M; Raiter Y; Abreu P; Ianos C; Chappell P
J Child Adolesc Psychopharmacol; 2022 Apr; 32(3):143-152. PubMed ID: 35394365
[No Abstract] [Full Text] [Related]
3. Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder.
Findling RL; Cavuş I; Pappadopulos E; Vanderburg DG; Schwartz JH; Gundapaneni BK; DelBello MP
J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):545-57. PubMed ID: 24111980
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder.
DelBello MP; Versavel M; Ice K; Keller D; Miceli J
J Child Adolesc Psychopharmacol; 2008 Oct; 18(5):491-9. PubMed ID: 18928413
[TBL] [Abstract][Full Text] [Related]
5. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.
Lee HB; Yoon BH; Kwon YJ; Woo YS; Lee JG; Kim MD; Bahk WM
Clin Drug Investig; 2013 Oct; 33(10):743-53. PubMed ID: 23990283
[TBL] [Abstract][Full Text] [Related]
7. Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder.
Karayal ON; Glue P; Bachinsky M; Stewart M; Chappell P; Kolluri S; Cavus I
J Psychiatr Pract; 2011 Mar; 17(2):100-9. PubMed ID: 21430488
[TBL] [Abstract][Full Text] [Related]
8. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.
Keck PE; Versiani M; Potkin S; West SA; Giller E; Ice K;
Am J Psychiatry; 2003 Apr; 160(4):741-8. PubMed ID: 12668364
[TBL] [Abstract][Full Text] [Related]
9. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study.
Ketter TA; Sachs GS; Durgam S; Lu K; Starace A; Laszlovszky I; Németh G
J Affect Disord; 2018 Jan; 225():350-356. PubMed ID: 28843918
[TBL] [Abstract][Full Text] [Related]
10. Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study.
Findling RL; Cavuş I; Pappadopulos E; Vanderburg DG; Schwartz JH; Gundapaneni BK; DelBello MP
J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):531-44. PubMed ID: 24111983
[TBL] [Abstract][Full Text] [Related]
11. Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial.
Findling RL; Landbloom RL; Mackle M; Wu X; Snow-Adami L; Chang K; Durgam S
Paediatr Drugs; 2016 Oct; 18(5):367-78. PubMed ID: 27461426
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study.
Findling RL; Pathak S; Earley WR; Liu S; DelBello M
J Child Adolesc Psychopharmacol; 2013 Sep; 23(7):490-501. PubMed ID: 24024534
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania.
Keck PE; Versiani M; Warrington L; Loebel AD; Horne RL
J Clin Psychiatry; 2009 Jun; 70(6):844-51. PubMed ID: 19573482
[TBL] [Abstract][Full Text] [Related]
14. Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder.
Warrington L; Lombardo I; Loebel A; Ice K
CNS Drugs; 2007; 21(10):835-49. PubMed ID: 17850172
[TBL] [Abstract][Full Text] [Related]
15. A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder.
Biederman J; Mick E; Spencer T; Dougherty M; Aleardi M; Wozniak J
Bipolar Disord; 2007 Dec; 9(8):888-94. PubMed ID: 18076539
[TBL] [Abstract][Full Text] [Related]
16. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study.
Vieta E; Owen R; Baudelet C; McQuade RD; Sanchez R; Marcus RN
Curr Med Res Opin; 2010 Jun; 26(6):1485-96. PubMed ID: 20429835
[TBL] [Abstract][Full Text] [Related]
17. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.
Camm AJ; Karayal ON; Meltzer H; Kolluri S; O'Gorman C; Miceli J; Tensfeldt T; Kane JM
CNS Drugs; 2012 Apr; 26(4):351-65. PubMed ID: 22452529
[TBL] [Abstract][Full Text] [Related]
18. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
Bowden CL; Vieta E; Ice KS; Schwartz JH; Wang PP; Versavel M
J Clin Psychiatry; 2010 Feb; 71(2):130-7. PubMed ID: 20122373
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial.
Pathak S; Findling RL; Earley WR; Acevedo LD; Stankowski J; Delbello MP
J Clin Psychiatry; 2013 Jan; 74(1):e100-9. PubMed ID: 23419231
[TBL] [Abstract][Full Text] [Related]
20. A 52-Week Study of Olanzapine with a Randomized Behavioral Weight Counseling Intervention in Adolescents with Schizophrenia or Bipolar I Disorder.
Detke HC; DelBello MP; Landry J; Hoffmann VP; Heinloth A; Dittmann RW
J Child Adolesc Psychopharmacol; 2016 Dec; 26(10):922-934. PubMed ID: 27676420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
